We would like to inform you that we have decided to amend the terms and conditions of the current Terms and Conditions of the Usage License for a Healthy Human-derived iPS Cell Line for Research (CFiS Series), and would like to inform you of the amendment as follows in accordance with the procedure of Article 14 of the current Terms and Conditions.

Summary of an Amendment

The following addition has been made.

Article 1 Section 6: Addition of Prohibited Conduct Regarding Use of the Material

【On the Amendment】
Add the following as sub-section (6)

(6)The use of cell culture supernatants extracted or secreted from the Material or the Differentiated cells for research or treatment conducts, performance or activities for the purpose of beauty, anti-aging, hair growth, or fatigue recovery, or for manufacture of pharmaceuticals, regenerative medicinal products, quasi-drugs, cosmetics or food and such equivalents in its relevant local jurisdiction for the purpose of beauty, anti-aging, hair growth, or fatigue recovery by using such materials.

Date of Application of the Amended Terms and Conditions

The amended terms and conditions will be effective as of July 14, 2025.

【The revised terms and conditions 】
Terms and Conditions of the Usage License for a Healthy Human-derived iPS Cell Line for Research (CFiS Series)

Summary of Impact on Customers

As a result of this amendment, the amended terms and conditions will apply to new contract on and after the effective date. Existing users also shall comply with the amended terms and conditions with respect to usage on and after the effective date. If you have any questions regarding the amendment, please contact us.

Contact Information

If you have any questions or concerns regarding the amendment of these Terms and Conditions of the Usage License for a Healthy Human-derived iPS Cell Line for Research (CFiS Series), please contact the following ;

CiRA Foundation
Email: minnano-saibou*cira-foundation.or.jp
(please change the * to @)